TL;DR: A personalized mRNA therapy called intismeran autogene plus Keytruda cut melanoma recurrence or death risk by 42% in a Phase 3 trial of 1,137 surgically treated patients.

Personalized mRNA Shot Cuts Melanoma Return in Large Trial

A personalized mRNA cancer treatment met its main goals in a late-stage melanoma trial, reducing recurrence and distant spread when added to standard immunotherapy after surgery. Drugmakers Moderna and Merck reported detailed Phase 3 INTerpath-001 results on Oct. 22, 2026, showing a 42% lower risk of recurrence or death and a 38% lower risk of distant metastasis or death compared with Keytruda alone, according to AJMC.

The outcome marks the first positive Phase 3 readout described to date for an individualized neoantigen therapy and for an mRNA-based cancer therapy, according to a Moderna company announcement. The study enrolled patients whose high-risk skin melanoma had been completely removed by surgery and who had not received prior systemic therapy. Researchers then tested whether a custom-built mRNA that teaches the immune system to recognize each tumor's mutations could keep cancer from returning.

The full numbers are now public after an initial topline announcement in August. The detailed data were slated for presentation during Presidential Symposium I at the European Society for Medical Oncology Congress 2026 and have been accepted for publication in The New England Journal of Medicine, according to AJMC.

What the trial tested

INTerpath-001, also listed as NCT05933577, enrolled 1,137 patients with completely resected stage IIB, IIC, III or IV cutaneous melanoma, according to AJMC. Patients were randomly assigned 2:1 after surgery to receive either the experimental combination or a control regimen for approximately one year.

In the experimental arm, patients received intismeran autogene at 1 mg every three weeks for up to nine doses plus pembrolizumab at 400 mg every six weeks for up to nine cycles. In the control arm, patients received placebo plus pembrolizumab on the same immunotherapy schedule, according to AJMC. Pembrolizumab, sold as Keytruda, is Merck's anti-PD-1 therapy.

The approach is adjuvant therapy, meaning treatment given after surgery when many cancers are considered most treatable, with the goal of increasing the possibility of cure, according to the Moderna company announcement. The trial's primary endpoint was recurrence-free survival, or RFS, with distant metastasis-free survival, or DMFS, as a key secondary endpoint. Overall survival remains under follow-up.

How large was the benefit?

After a median follow-up of 24.6 months, intismeran plus pembrolizumab lowered the risk of recurrence or death with a hazard ratio of 0.58, corresponding to a 42% reduction, with a 95% confidence interval of 0.45 to 0.75 and a two-sided p-value below .001, according to AJMC.

The combination also lowered the risk of distant metastasis or death with a hazard ratio of 0.62, corresponding to a 38% reduction, with a 95% confidence interval of 0.45 to 0.85 and a two-sided p-value of .002, according to AJMC. Median RFS and DMFS had not been reached in either treatment arm at the analysis point.

Absolute rates at two years showed separation between the groups. The two-year RFS rate was 82.2% with intismeran plus pembrolizumab versus 70.0% with pembrolizumab alone, according to AJMC. The two-year DMFS rates were 88.5% and 80.2%, respectively. Investigators reported that improvements were generally consistent across prespecified subgroups.

Overall survival data are not yet mature, although the companies reported a favorable trend for the combination, according to AJMC. The study remains ongoing to further evaluate overall survival and other key endpoints, according to the Moderna company announcement.

Why benefit grew after six months

One of the most discussed details is timing. During the first six months, efficacy looked comparable between the two arms, according to AJMC. The hazard ratio for recurrence or death in that early window was 0.99, with a 95% confidence interval of 0.66 to 1.49, while the hazard ratio for distant metastasis or death was 1.01, with a 95% confidence interval of 0.58 to 1.79.

After six months, following completion of the intismeran immunization regimen, the curves separated. In a prespecified sensitivity analysis, the addition of intismeran reduced the risk of recurrence or death by 58%, with a hazard ratio of 0.42 and a 95% confidence interval of 0.30 to 0.58, compared with Keytruda alone, according to AJMC. In the same post-six-month analysis, the risk of distant metastasis or death was reduced by half, with a hazard ratio of 0.50 and a 95% confidence interval of 0.34 to 0.73.

A separate prespecified analysis of the modified intention-to-treat population, which excluded participants who did not receive at least one dose of intismeran or placebo as planned, showed a 49% reduction in recurrence or death risk, with a hazard ratio of 0.51 and a 95% confidence interval of 0.39 to 0.67, according to AJMC. In that population, distant metastasis or death risk was reduced by 45%, with a hazard ratio of 0.55 and a 95% confidence interval of 0.40 to 0.77.

That pattern fits the biological idea behind a multi-dose personalized vaccine: immune training takes months to complete before clinical separation becomes visible. The Associated Press reporting on the trial, in its article titled "A cancer treatment using mRNA succeeded in a late-state trial," similarly described a vaccine custom-brewed for each patient and tested alongside Keytruda immunotherapy.

How the personalized mRNA works

Intismeran autogene, also identified as V940 or mRNA-4157, is an mRNA-based individualized neoantigen therapy jointly developed by Merck and Moderna, according to the Moderna company announcement. It is designed specifically for each patient based on the unique set of mutations within that patient's tumor.

The manufacturing process starts with a patient's own tumor sample. Sequencing identifies the tumor's mutational signature, and a synthetic mRNA is then constructed to encode up to 34 tumor-specific neoantigens, according to AJMC. Once injected, the mRNA instructs the patient's cells to produce copies of those mutation markers so immune cells can learn to seek and destroy residual cancer cells.

Keytruda works through a complementary mechanism. It blocks PD-1, removing a brake that cancer cells use to hide from immune attack, while the vaccine supplies new targets for tumor-specific T cells. That combination rationale was central to INTerpath-001 and to the earlier Phase 2b program.

The trial's principal investigator, Professor Georgina Long, medical director of Melanoma Institute Australia and chair of melanoma medical oncology and translational research at the University of Sydney, said the treatment was designed based on the unique mutational fingerprint of a patient's own tumor, according to the Moderna company announcement. Long said the combination has the potential to establish a new treatment paradigm in the adjuvant melanoma setting by helping patients remain cancer-free for longer.

Safety profile in detail

Safety was closely watched because the regimen adds repeated mRNA injections to a year of PD-1 blockade. Treatment-related adverse events occurred in 95.8% of patients receiving the combination and 90.0% of those receiving pembrolizumab alone, according to AJMC. Grade 3 to 5 treatment-related events occurred in 14.2% and 13.4%, respectively.

The most common adverse events with the combination were pyrexia at 52.2%, injection-site pain at 51.0% and fatigue at 38.5%, according to AJMC. The companies said no new safety signals were observed and described the safety profile as generally consistent with previously reported studies of the combination, according to the Moderna company announcement.

That earlier experience includes the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial in adjuvant melanoma. Five-year follow-up from that smaller study, presented at the 2026 American Society of Clinical Oncology annual meeting, showed a 49% lower risk of recurrence or death, with a hazard ratio of 0.51, and a 59% lower risk of distant metastasis or death, with a hazard ratio of 0.411, versus pembrolizumab alone, according to AJMC. The Phase 3 safety findings did not alter the known profile from that combination experience.

What happens next for approval

Merck and Moderna said they plan to present the INTerpath-001 data at an international medical meeting and engage with regulators on filing submissions for intismeran autogene in combination with Keytruda, according to the Moderna company announcement. The detailed results were selected for an official ESMO press briefing as late-breaking results, identified as Presentation LBA1, and accepted by The New England Journal of Medicine, according to AJMC.

The companies are pursuing a broader INTerpath clinical development program. It currently consists of nine Phase 2 and Phase 3 trials across multiple tumor types and disease stages, including melanoma, non-small cell lung cancer, bladder cancer and renal cell carcinoma, according to the Moderna company announcement. AJMC reported that three ongoing Phase 3 trials are testing intismeran in non-small cell lung cancer.

Market reaction underscored both enthusiasm and high expectations. Reuters reported in August that Moderna shares surged as much as 160% after the initial announcement that the trial met its recurrence and spread goals, while Merck shares also rose. After the detailed October release, AJMC noted that the primary result landed at the low end of some investor expectations anchored on the Phase 2b hazard ratio, with Moderna shares falling sharply that day. Those share moves do not change the clinical findings, but they show how closely investors are watching whether personalized neoantigen therapy can extend beyond melanoma.

For patients, the immediate meaning is narrower: among people with completely removed stage IIB through IV melanoma, adding a tumor-matched mRNA course to a year of Keytruda lowered the chance of cancer returning or spreading during about two years of follow-up. Longer follow-up will determine whether that early advantage translates into an overall survival advantage.

Sources referenced